MarketCapExport financials
Check-Cap Ltd. (CHEK)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Check-Cap Ltd. Balance Sheet 2025-2011 | CHEK
Brief overview of Check-Cap Ltd.'s assets and capital
Balance sheet changes are traced across five available annual reports between 2016 and 2023.
Assets advanced +103.5% to $25 million from $12.3 million; annual growth near 10.7% reflects a fast increase in scale.
Liabilities grew more slowly than assets: -29.6% versus +103.5%. Expansion relied more on equity, improving funding quality.
The equity-to-assets ratio is 94.7%, compared with 84.6% five periods ago. The balance sheet has a substantial internal cushion.
Cash accounts for 35.4% of assets versus 94.7% initially. The change indicates the degree of financial flexibility.
The accumulated result is -$144.9 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall picture
The indicators point to a strong balance sheet position for Check-Cap Ltd.: funding is balanced and liability risks appear controlled.
Annual Balance Sheet Check-Cap Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -3.13 M | - | - | - | - | - | -11.6 M | -9.39 M | -1.08 M | -4.98 M | -4.58 M | - |
Long Term Debt |
- | 16 K | - | 627 K | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
16 K | 120 K | - | 337 K | - | 264 K | 222 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 16 K | - | 721 K | 927 K | 279 K | 393 K | 185 K | 439 K | 521 K | 577 K | 2.73 M | 3.16 M | 2.58 M | - |
Total Current Liabilities |
4.05 M | 1.81 M | 1.33 M | 3.41 M | 4.04 M | 2.98 M | 2.8 M | 2.22 M | 1.56 M | 1.37 M | 2.07 M | - | - | - | - |
Total Liabilities |
- | 1.83 M | 1.33 M | - | - | - | 3.2 M | 2.41 M | 2 M | 1.89 M | 2.65 M | 5.56 M | 4.18 M | 3.37 M | - |
Retained Earnings |
-166 M | -170 M | -145 M | -127 M | -108 M | -91 M | -77.1 M | -63.3 M | -52.7 M | -42.9 M | -34.1 M | -26.6 M | -22.5 M | -18.5 M | - |
Total Assets |
7.49 M | 377 K | 25 M | 45.4 M | 55.7 M | 19.6 M | 9.43 M | 15.4 M | 7.91 M | 12.3 M | 15.3 M | 7.78 M | 5.38 M | 8.5 M | - |
Cash and Cash Equivalents |
2 K | - | 8.84 M | 4.09 M | - | 7.7 M | 7.68 M | 8.57 M | 7 M | 11.6 M | 9.39 M | 1.08 M | 4.98 M | - | - |
Book Value |
7.49 M | -1.45 M | 23.7 M | 45.4 M | 55.7 M | 19.6 M | 6.23 M | 13 M | 5.9 M | 10.4 M | 12.6 M | 2.23 M | 1.19 M | 5.13 M | - |
Total Shareholders Equity |
3.44 M | -1.45 M | 23.7 M | 41.3 M | 50.7 M | 16.4 M | 6.23 M | 13 M | 5.9 M | 10.4 M | 12.6 M | -826 K | -528 K | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Check-Cap Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 16 K | 16 K | - | - | - | - | - | - | - | 795 K | - | 815 K | - | 125 K | - | 121 K | - | 211 K | - | 236 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 16 K | 16 K | - | - | - | - | - | - | - | 927 K | - | 1 M | - | 279 K | - | 298 K | - | 393 K | - | 424 K | - | 185 K | - | 464 K | - | 439 K | - | 570 K | - | 521 K | - | 564 K | - | 577 K | - | - | - | 951 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | 1.83 M | - | 1.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-166 M | -165 M | -170 M | -151 M | -145 M | -139 M | - | - | - | - | -108 M | - | -98.5 M | - | -91 M | - | -83.5 M | - | -77.1 M | - | -69.8 M | - | -63.3 M | - | -57.5 M | - | -52.7 M | - | -48.4 M | - | -42.9 M | - | -38.8 M | - | -34.1 M | - | - | - | -21.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
7.49 M | 5.76 M | 377 K | 18.1 M | 25 M | 33.7 M | - | - | - | - | 55.7 M | - | 32.6 M | - | 19.6 M | - | 17.9 M | - | 9.43 M | - | 15.9 M | - | 15.4 M | - | 20.8 M | - | 7.91 M | - | 10.1 M | - | 12.3 M | - | 10.7 M | - | 15.3 M | - | - | - | 2.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
2 K | 1.16 M | - | 17.8 M | 8.84 M | 2.25 M | - | - | - | - | 26.5 M | - | 10.1 M | - | 7.7 M | - | 8.39 M | - | 7.68 M | - | 8.32 M | - | 8.57 M | - | 9.96 M | - | 7 M | - | 9.15 M | - | 11.6 M | - | 8.44 M | - | 9.39 M | - | 19.1 M | - | 1.08 M | - | - | - | 4.98 M | - | - | - | 4.58 M | - | - | - | - | - | - | - |
Book Value |
7.49 M | 5.76 M | -1.45 M | 18.1 M | 23.7 M | 33.7 M | - | - | - | - | 55.7 M | - | 32.6 M | - | 19.6 M | - | 17.9 M | - | 9.43 M | - | 15.9 M | - | 15.4 M | - | 20.8 M | - | 7.91 M | - | 10.1 M | - | 12.3 M | - | 10.7 M | - | 15.3 M | - | - | - | 2.98 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
3.44 M | 3.76 M | -1.45 M | 17.2 M | 23.7 M | 30.2 M | - | - | - | - | 50.7 M | - | 28.3 M | 32.1 M | 16.4 M | - | 15 M | 7.66 M | 6.23 M | - | 13.3 M | 16.5 M | 13 M | - | 18.5 M | 3.34 M | 5.9 M | - | 7.63 M | - | 10.4 M | - | 8.72 M | - | 12.6 M | - | 17.7 M | - | -826 K | - | - | - | -528 K | - | - | - | 2.78 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Check-Cap Ltd., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Senseonics Holdings
SENS
|
$ 8.58 | 7.38 % | $ 358 M |  USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
$ 2.17 | -10.91 % | $ 143 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 694.85 | 2.62 % | $ 262 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Trinity Biotech plc
TRIB
|
$ 6.07 | 2.97 % | $ 2.18 B |  Irlanda |
 |
Brainsway Ltd.
BWAY
|
$ 11.12 | 4.81 % | $ 378 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.2 | 3.39 % | $ 25.2 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 458.04 | 1.06 % | $ 27.3 B | USA |
 |
Exagen
XGN
|
$ 5.79 | -23.82 % | $ 125 M | USA |
 |
Guardant Health
GH
|
$ 151.28 | -1.4 % | $ 19 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 366.98 | 1.02 % | $ 30.5 B | USA |
 |
IQVIA Holdings
IQV
|
$ 271.72 | 2.59 % | $ 46.7 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M |  Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Celcuity
CELC
|
$ 66.73 | 3.9 % | $ 3.12 B | USA |
 |
DexCom
DXCM
|
$ 79.42 | -5.97 % | $ 31 B | USA |
 |
Agilent Technologies
A
|
$ 175.14 | 1.97 % | $ 49.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 32.49 | -4.99 % | $ 942 M | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.16 | 4.29 % | $ 103 K | USA |
|
Biodesix
BDSX
|
$ 8.51 | -57.13 % | $ 64.3 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.15 | 4.54 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
$ 10.61 | -0.66 % | $ 707 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 23.68 | 26.9 % | $ 729 M | USA |
 |
CareDx, Inc
CDNA
|
$ 78.47 | 2.8 % | $ 4.18 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.61 | -1.55 % | $ 4.69 M | USA |
 |
Interpace Biosciences
IDXG
|
$ 7.0 | -13.43 % | $ 31 M | USA |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 204.67 | 1.5 % | $ 16.1 B | Irlanda |
 |
Co-Diagnostics
CODX
|
$ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 13.2 | -0.38 % | $ 139 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
$ 2.4 | -11.93 % | $ 9.56 M | Israel |
 |
Myriad Genetics
MYGN
|
$ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
$ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
$ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.3 | -5.35 % | $ 690 M | USA |